Nirmatrelvir (Paxlovid) Mini-HTA for the treatment of COVID-19.
Loading...
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Keralty
Abstract
COVID-19 antiviral treatments are still in the early stages of development, considering that the disease was first identified in late 2019. COVID-19 nirmatrelvir is recommended for use in patients older than 12 years and weighing more than 40 kilograms with risk factors for moderate COVID-19 and who already have a positive COVID-19 test.
The risks of using nirmatrelvir appear to be lower than the potential benefits.